The United Nations AIDS program announced on Wednesday, July 18th, 2012 that fewer people infected with HIV globally were dying, particularly in sub-Saharan Africa. The reason for this encouraging news is the greater accessibility for patients with AIDS worldwide to crucial antiretroviral drugs. The U.N. is actively working alongside pharmaceutical companies, in an effort to[…]
Tesamorelin and Breaking News from the United Nations AIDS Program
Anti-Retroviral / Anti-HIV, Antiviral Tags: antiretroviral therapyHIV Jul 19, 2012
The Facts About Herpes and Treatment with Famciclovir
Anti-Retroviral / Anti-HIV, Antiviral, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2015 Tags: CDC Jul 18, 2012
As an effectual antiviral drug, Famciclovir, CAS number 104227-87-4, is a key treatment for infections caused by the herpes virus. Novartis holds the patent for Famvir, which is the brand name for famciclovir, but that is expiring on September 1, 2015. While famciclovir is not a cure for herpes, it will slow the growth and[…]
Darunavir Ethanolate continues to Prove it's Viability for HIV Treatment
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API Tags: antiretroviralDarunavir EthanolateHIV infectionRitonavir Apr 23, 2012
Darunavir Ethanolate is also known by it’s brand name Prezista, and is used to treat HIV infection. In the class of protease inhibitors, darunavir ethanolate was approved by the FDA in June of 2006. What makes darunavir ethanolate unique is it’s ability to combat drug resistant strains of HIV in affected patients, as well as[…]
